As Nektar (NKTR)
has gotten investors more excited about its pipeline, including a
somewhat surprising success with its late-stage pain drug NKTR-181, the
shares have done all right since the fall of 2016 – rising more than a third since then (in line with the SPDR S&P Biotech (XBI) and ahead of the iShares Nasdaq Biotechnology (IBB)).
The shares don’t look so undervalued to me now, but there are still
multiple drivers in the queue for key pipeline candidates that could
drive meaningful value.
Continue here:
Nektar Therapeutics Building A More Exciting Pipeline
No comments:
Post a Comment